JAK2 and essential thrombocythemia: ET shares with other MPNs the classical driver mutations affecting genes like Janus kinase (JAK2 V617F; 50–60%), calreticulin (CALR; 25–35%), or myeloproliferative leukemia (MPL; 5–10%) [4,5,6,7].